Clinical Trials

June 11, 2018

A Randomized, Double-Blind, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of Pulsed, Inhaled Nitric Oxide (INO) in Subjects with Pulmonary Hypertension Associated with Pulmonary Fibrosis on Long Term Oxygen Therapy (Part 1 and Part 2)

• Study Sponsor: Bellerophon Therapeutics
• Institution: Bellerophon Therapeutics
• Start Date: Friday, Dec. 22, 2017
• End Date: Friday, Aug. 31, 2018
• Design: Placebo-controlled
• Age range (years): from 18 to 80
• Type of PH
  • PH with lung involvement (Group 3)
• Study Duration for individual patient: 9 weeks
• Contact: http://patients.bellerophon.com/
• Listing on clinicaltrials.gov